Journal
FUTURE ONCOLOGY
Volume 15, Issue 30, Pages 3503-3511Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2019-0352
Keywords
bone metastasis; osteonecrosis of jaw; risk factor; zoledronic acid
Categories
Funding
- National Natural Science Foundation of China [81673102, 81602791, 81803164]
- National Key Research and Development Program of China [2016YFC0105409]
- Youth Foundation of Shanghai Health and Family Planning Commission [20164Y0066]
- Clinical Research Plan of SHDC [16CR1037B]
- Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20171904]
- Shanghai Jiaotong University Translational Medicine Fund Support [ZH2018QNA54]
- special construction of integrated Chinese and Western medicine in general hospital [ZHYY-ZXYJHZ X-2-201704]
Ask authors/readers for more resources
Aim: To investigate the risk factors for developing osteonecrosis of jaw (ONJ) in advanced cancer patients with bone metastases underwent zoledronic acid (ZA) treatment. Materials & methods: Univariate and multivariate logistic regression analyses were performed to investigate factors associated with developing ONJ in advanced cancer patients. Results: A total of 2214 advanced cancer patients were included. Univariate and multivariate logistic regression analyses for risk factors associated with ONJ were older age (>= 66 years, hazards ratio [HR]: 3.21; p = 0.007), anemia (HR: 3.29; p = 0.006) and duration of ZA exposure (between 1 and 2 years, HR: 3.91, p = 0.01; >= 2 years, HR: 8.07, p < 0.001), respectively. Conclusion: Patients with older age, anemia and/or more than 1 year of ZA treatment are at high risk of developing ONJ.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
